Even though there are studies showing an effective and safe reduction of glycaemic parameters with initial combination therapies with DPP-4 inhibitors, initial combinations are not generally recommended in the new treatment recommendations (7072, 7685)
Compounding pharmacies will not dispense lipo C without a valid prescription
Select your favorite store to: There are no workshops coming soon
The Mississippi Division of Medicaids criteria for select obesity agents, effective April 1, 2026, cover Saxenda or Wegovy as preferred agents for ages 12 and older, one product at a time, with initial and renewal authorizations of 12 months each
Ongoing monitoring protocols typically include symptom assessment, enzyme checks at intervals, and clear patient education on warning signs such as epigastric pain, nausea, or elevated triglycerides